Canaccord Genuity analyst Sumant Kulkarni maintained a Buy rating on Biohaven Pharmaceutical Holding Co (NYSE:BHVN) Ltd on Sunday, setting a price target of $110, which is approximately 16.39% above the present share price of $94.51.
Kulkarni expects Biohaven Pharmaceutical Holding Co Ltd to post earnings per share (EPS) of -$3.27 for the fourth quarter of 2020.
The current consensus among 7 TipRanks analysts is for a Strong Buy rating of shares in Biohaven Pharmaceutical Holding Co, with an average price target of $92.
The analysts price targets range from a high of $110 to a low of $63.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $17.66 million and a net profit of -$163.16 million. The company's market cap is $5.66 billion.
According to TipRanks.com, Canaccord Genuity analyst Sumant Kulkarni is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 22.9% and a 52.55% success rate.
Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.